Larysa V Kostyuchenko

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2520217/publications.pdf

Version: 2024-02-01

1040056 940533 19 577 9 16 citations h-index g-index papers 19 19 19 1046 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	DOCK8 Deficiency: Clinical and Immunological Phenotype and Treatment Options - a Review of 136 Patients. Journal of Clinical Immunology, 2015, 35, 189-198.	3.8	284
2	Nijmegen Breakage Syndrome: Clinical and Immunological Features, Long-Term Outcome and Treatment Options – a Retrospective Analysis. Journal of Clinical Immunology, 2015, 35, 538-549.	3.8	73
3	Distinct molecular response patterns of activating STAT3 mutations associate with penetrance of lymphoproliferation and autoimmunity. Clinical Immunology, 2020, 210, 108316.	3.2	40
4	Genetic characteristics of eighty-seven patients with the Wiskott–Aldrich syndrome. Molecular Immunology, 2011, 48, 788-792.	2.2	35
5	Heterozygous activating mutation in RAC2 causes infantile-onset combined immunodeficiency with susceptibility to viral infections. Clinical Immunology, 2019, 205, 1-5.	3.2	27
6	Molecular Characteristics, Clinical and Immunologic Manifestations of 11 Children with Omenn Syndrome in East Slavs (Russia, Belarus, Ukraine). Journal of Clinical Immunology, 2016, 36, 46-55.	3.8	19
7	Fifteen Years of the J Project. Journal of Clinical Immunology, 2019, 39, 363-369.	3.8	16
8	The Clinical and Genetic Spectrum of 82 Patients With RAG Deficiency Including a c.256_257delAA Founder Variant in Slavic Countries. Frontiers in Immunology, 2020, 11, 900.	4.8	16
9	Hematopoietic Stem Cell Transplantation Positively Affects the Natural History of Cancer in Nijmegen Breakage Syndrome. Clinical Cancer Research, 2021, 27, 575-584.	7.0	13
10	Geographical Distribution, Incidence, Malignancies, and Outcome of 136 Eastern Slavic Patients With Nijmegen Breakage Syndrome and NBN Founder Variant c.657_661del5. Frontiers in Immunology, 2020, 11, 602482.	4.8	13
11	A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune \hat{A}° , a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency. Journal of Clinical Immunology, 2017, 37, 539-547.	3.8	9
12	Simple Measurement of IgA Predicts Immunity and Mortality in Ataxia-Telangiectasia. Journal of Clinical Immunology, 2021, 41, 1878-1892.	3.8	9
13	TREC/KREC levels in children with ataxia-telangiectasia. Immunologic Research, 2021, 69, 436-444.	2.9	7
14	The Konya Declaration for Patients with Primary Immunodeficiencies. Journal of Clinical Immunology, 2020, 40, 770-773.	3.8	5
15	Nijmegen Breakage Syndrome (NBS1). , 2019, , 1-6.		4
16	Clinical and immunological presentation of ataxia-telangiectasia. Archives of the Balkan Medical Union, 2020, 55, 573-581.	0.2	4
17	Impact of the J Project on progress of primary immunodeficiency care in Ukraine. Central-European Journal of Immunology, 2021, 46, 250-257.	1.2	3
18	Nijmegen Breakage Syndrome (NBS1). , 2020, , 506-511.		0

ARTICLE IF CITATIONS

19 ĐŸÑ€Đ¾Đ±Đ»ĐμĐ¼Đ½Ñ‹Đμ Đ²Đ¾Đ¿Ñ€Đ¾ÑÑ‹ Ñ€Đ°Đ½Đ½ĐμĐ¹ ĐиаĐ³Đ½Đ¾ÑÑ,иаи аÑ,ааÑииଐ,⊅μĐ»ĐμаĐ½Đ